News

Combining light-activated cancer drugs with tumor-seeking antibodies could provide a more effective way of treating many cancers, according to new research.

Helicos BioSciences Corporation has joined an educational and advocacy group dedicated to advancing the understanding and adoption of personalized medicine.

The collaborators expect to enhance integration of basic science and clinical research through this new alliance.

Researchers have identified the enzyme sphingosine kinase 2 as a possible new therapeutic target to improve the efficacy of chemotherapy for colon and breast cancer.

Asuragen gains right to develop, manufacture and market products for the diagnosis, stratification and monitoring of patients with AML.

Quest Diagnostics licenses the heteroduplex tracking technology underlying Pathway's SensiTrop™ HIV co-receptor tropism test.

Potential to halt cancer cell growth without interfering with insulin may address limitations of current IGF inhibitors.

The clinical trial was designed to demonstrate that the ovarian triage test is a useful adjunct for distinguishing benign from malignant ovarian tumors.

Premier gave its 1,700 hospital members access in August to the Roche COBAS® Ampliprep/COBAS® TaqMan® HIV-1 assay.

The fund will develop 50 new quantitative, multiplexed immunoassays for cancer-related proteins to be added to the automated RBM HumanMAP® platform.